Do you know which factors influence your risk of coronary artery disease?

Learn more about the geneType™ coronary artery disease test which goes beyond hereditary risk, looking at genetic and clinical risk factors to give you a comprehensive risk prediction so that you can take preventative steps to improve health and mitigate your risk.
It is with a comprehensive risk assessment that you and your health provider may be able to enable effective management of modifiable risk factors.1
geneType™ for Coronary Artery Disease is appropriate for:
geneType™ reports help you and your health provider translate your personal clinical, family and genetic data into an actionable preventable health plan.
Unlike other tests, your test results are provided in simple language that you can understand.
Key features of the report:
Risk reducing options exist for adults at borderline, intermediate and high risk of coronary artery disease.
If your question is not shown here, please Contact us directly.
No. At this time geneType™ is a self-pay test. However, you may use FSA/HSA to pay for the test.
Coronary artery disease is a multifactorial disease and it is not possible to incorporate all potential risk factors into a risk prediction model. Test results should be interpreted by a health provider in the context of your clinical and family history.
Yes.
While there are other companies out there that provide random lists of genetic markers that are associated with coronary artery disease, there are no checks and balances associated with the results they provide. Most of the markers they pull from peer-reviewed publications without cross validating the markers. And more importantly, geneType™ goes through rigorous statistical validation of the genetic component prior to integrating it into the full model. The fully integrated geneType™ model is then validated separately.
*Patient eligibility dependent on personal medical history, age and sex
The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for eight diseases in the panel; a man would be eligible for seven. Starting at age 30, a patient may qualify for geneType’s™ cancer risk assessments only.
1. John Hopkins Medicine. Coronary Artery Disease: Prevention, Treatment and Research. Accessed June 2022.
2. Fryar CD et al. NCHS Data Brief 2012(103):1-8.
Accredited For Compliance With NPAAC Standards And ISO 15189